Cullen/Frost Bankers’s Emergent Biosolutions EBS Stock Holding History

Cullen/Frost Bankers’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-282	Closed	-$14K	–	1222
2021 Q3	$14K	Hold	282	–	–	﹤0.01%	1029
2021 Q2	$18K	Sell	282 -2,899	-91%	-$186K	﹤0.01%	1004
2021 Q1	$296K	Sell	3,181 -1,198	-27%	-$123K	0.01%	470
2020 Q4	$392K	Buy	4,379 +1,450	+50%	+$133K	0.01%	390
2020 Q3	$303K	Buy	2,929 +541	+23%	+$58.3K	0.01%	404
2020 Q2	$189K	Buy	+2,388	New	+$178K	0.01%	452

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cullen/Frost Bankers's EBS Position: Q4 2021 in Review

Cullen/Frost Bankers sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 282 shares — an estimated $14K sold.

Cullen/Frost Bankers first reported a position in EBS in Q2 2020 and held it in 6 quarters. The position peaked at $392K in Q4 2020. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

Cullen/Frost Bankers reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
Cullen/Frost Bankers sold 282 Emergent Biosolutions shares in Q4 2021, an estimated $14K.
Cullen/Frost Bankers first reported a position in Emergent Biosolutions in Q2 2020 and held it in 6 quarters.
Cullen/Frost Bankers's Emergent Biosolutions position peaked at $392K in Q4 2020.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Cullen/Frost Bankers's 13F filing for Q4 2021, filed 7 Feb 2022.